Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp T.IGX

Alternate Symbol(s):  IGXT

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

RedHill Biopharma and IntelGenx Receive Complete Response Letter From FDA for RHB-103 Oral Film for Acute Migraines

Globe Newswire February 4, 2014

TrendingWallStreet.com Announces Volume Coverage on PGNX, MTOR, IGXT, and VRNG

Accesswire January 30, 2014

IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products

Globe Newswire January 13, 2014

IntelGenx Announces Additional Development and Commercialization Agreement with Par Pharmaceutical, Inc. for Two More Products

Newsfile January 13, 2014

IntelGenx Grants Stock Options

Globe Newswire January 9, 2014

IntelGenx Grants Stock Options

Newsfile January 9, 2014

IntelGenx Closes $3.5 Million Public Offering

Newsfile December 16, 2013

IntelGenx Announces Public Offering of $3,500,000 of Common Stock

Globe Newswire December 12, 2013

IntelGenx Announces Public Offering of $3,500,000 of Common Stock

Newsfile December 12, 2013

IntelGenx Grants Stock Options

Globe Newswire December 4, 2013

IntelGenx Grants Stock Options

Newsfile December 4, 2013

IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights

Globe Newswire November 8, 2013

IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights

Newsfile November 8, 2013

IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint

Globe Newswire August 26, 2013

IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint

Newsfile August 26, 2013

IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL(TM)

Globe Newswire August 22, 2013

IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL(TM)

Newsfile August 22, 2013

IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights

Globe Newswire August 8, 2013

IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights

Newsfile August 8, 2013

IntelGenx Grants Stock Options

Globe Newswire August 7, 2013